EGFR and non-small cell lung carcinoma: Two previous studies (JO25567 and NEJ026) both showed that erlotinib in combination with bevacizumab resulted in a significantly longer median PFS than erlotinib alone in untreated advanced EGFR-mutated NSCLC (16–17 months vs. 9–13 months) [15,17].